ハムスターのプレプログルカゴンは,グルカゴンと2つの関連ペプチドの配列を含んでいます
Nature
|April 21, 1983
まとめ
研究者らは,前駆ホルモンであるハムスターの臓プレプログルカゴン (プレプログルカゴン) の構造を決定した. この発見は,組織特異な処理を通じて異なる組織に存在する様々なグルカゴン関連ペプチドの共通の起源を示唆しています.
科学分野:
- エンドクリノロジー エンドクリノロジー
- 分子生物学は分子生物学である.
- バイオケミストリー バイオケミストリー
背景:
- グルカゴンは,グルコース代謝を調節する臓ホルモンです.
- グルカゴンは,より大きな前体分子から合成されます.
- グルカゴンのようなペプチドは,様々な哺乳類の組織に含まれています.
研究 の 目的:
- ハムスターの臓プレプログルカゴンの構造を決定するために.
- 臓と非臓のグルカゴン関連ペプチドの関係を解明する.
主な方法:
- ハムスターの臓プレプログルカゴンによるcDNA配列解析.
- 先駆者のアミノ酸配列の分析.
主要な成果:
- 180アミノ酸のプレプレグルカゴン前駆体には,グルカゴンと2つのグルカゴンのようなポリペプチドが含まれています.
- 前駆体には,非臓のグルカゴンを含むポリペプチドの配列も含まれています.
- 臓のプログルカゴンのための処理スキームが提案されました.
結論:
- 哺乳類のグルカゴンおよび関連ペプチドは,共通の前駆体から派生する可能性がある.
- 組織特異的な処理が,グルカゴンに関連するペプチドの多様性を説明している可能性が高い.
- 決定された構造は,グルカゴン生物合成と機能を理解するのに役立ちます.
関連する概念動画
Insulin Secretory Vesicles
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...


